Condition

Recurrent Diffuse Large B-Cell Lymphoma clinical trials and research

• 20Clinical trials
• 1New in 30 days
• 2Countries

Newest Recurrent Diffuse Large B-Cell Lymphoma clinical trials

All recruiting trials (20)

• Natalizumab to help prevent brain-related side effects during CAR-T therapy in certain lymphoma patients

  This phase 2 study tests whether natalizumab can reduce severe ICANS in adults with recurrent or refractory DLBCL or MCL receiving CAR-T therapy.

  Recruiting Phase 2 University of Michigan Rogel Cancer Center · Ann Arbor, Michigan · NCT07892027

• Intrathecal Cytarabine and Hydrocortisone to Treat ICANS in NHL Patients Receiving CAR-T

  This trial tests whether giving cytarabine and hydrocortisone into the spine early after CAR-T therapy can reduce brain-related side effects in adults with non-Hodgkin lymphoma.

  Recruiting Phase 2 Vanderbilt-Ingram Cancer Center · Nashville, Tennessee · NCT07763210

• Lymphodepletion with low-dose whole-body radiation before standard CAR-T therapy for large B-cell lymphoma

  This early-phase trial tests if adding low-dose total body irradiation before standard lymphodepletion and tisagenlecleucel CAR-T therapy is safe and helps patients with relapsed or refractory large B-cell lymphoma see better responses.

  Recruiting Phase 1 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT07676877

• Fecal transplant to restore gut microbiome before CAR T therapy for relapsed or refractory B‑cell lymphoma

  This trial will test whether a fecal microbiome transplant can restore healthy gut bacteria and improve outcomes for adults with relapsed or refractory CD19 B‑cell lymphoma who received high‑risk antibiotics and are receiving CAR T‑cell therapy.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT07042438

• Epcoritamab with platinum chemotherapy and autologous stem cell transplant for relapsed or refractory large B-cell lymphoma

  This trial tests whether adding epcoritamab to standard platinum-based salvage chemotherapy followed by an autologous stem cell transplant helps adults with relapsed or refractory large B-cell lymphoma.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06905509

• Zanubrutinib plus sonrotoclax for relapsed or refractory B‑cell non‑Hodgkin lymphoma in underrepresented racial and ethnic groups

  This phase 1 trial tests whether combining zanubrutinib and sonrotoclax can help adults from underrepresented racial and ethnic groups whose B‑cell non‑Hodgkin lymphoma has returned or not responded to prior treatment.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT06859008

• Odronextamab with CAR T‑cell therapy for relapsed or refractory diffuse large B‑cell lymphoma

  This trial tests whether giving odronextamab before or after CAR T‑cell therapy helps adults with diffuse large B‑cell lymphoma that has relapsed or not responded to prior treatments.

  Recruiting Phase 2 University of California, Davis · Sacramento, California · NCT06854159

• Odronextamab as bridging therapy for relapsed or refractory large B‑cell lymphoma before CAR‑T

  This trial tests whether giving odronextamab before CAR‑T cell therapy can keep disease under control in adults with relapsed or refractory large B‑cell lymphomas.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT06784726

• ViPOR combination therapy for relapsed or refractory aggressive B‑cell lymphoma

  This treatment will try a five‑drug targeted combination called ViPOR (venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide) in adults whose aggressive B‑cell lymphoma has relapsed or not responded to prior therapy, focusing on specific genetic subtypes like CD10‑negative DLBCL and high‑grade B‑cell lympho

  Recruiting at 99 sites Phase 2 National Cancer Institute (NCI) · Tucson, Arizona and 114 other locations · NCT06649812

• Combination treatment of epcoritamab and ibrutinib for aggressive B-cell lymphoma

  This study is testing a new combination of two treatments, epcoritamab and ibrutinib, to see if they can help people with aggressive B-cell lymphoma that hasn't responded to other therapies.

  Recruiting at 3 sites Phase 1/2 Ohio State University Comprehensive Cancer Center · Minneapolis, Minnesota and 2 other locations · NCT06536049

• Treatment using modified T-cells for relapsed or refractory B-cell cancers

  This study is testing a new treatment that uses specially modified T-cells to see if it can help people with hard-to-treat B-cell cancers.

  Recruiting Phase 1 Mayo Clinic · Jacksonville, Florida · NCT06191887

• Injecting RC19D2 cells to treat advanced lymphoma

  This study is testing if injecting RC19D2 cells can be a safe treatment for people with advanced lymphoma that hasn't responded to other therapies.

  Recruiting Phase 1 Beijing Yongtai Ruike Biotechnology Company Ltd · Tianjin, Tianjin Municipality · NCT06047197

• Combining new drugs with standard treatment for relapsed large B-cell lymphoma

  This study is testing a new combination of drugs for people with large B-cell lymphoma that has come back or didn’t get better with earlier treatments to see if it works better than the usual options.

  Recruiting at 99 sites Phase 2 SWOG Cancer Research Network · Tucson, Arizona and 103 other locations · NCT05890352

• Bridging radiation therapy before CAR T-cell infusion for large B-cell lymphoma

  This study is testing whether giving radiation therapy before CAR T-cell treatment can help people with relapsed or hard-to-treat large B-cell lymphoma feel better and have better outcomes.

  Recruiting Early Phase 1 City of Hope Medical Center · Duarte, California · NCT05800405

• Treatment for relapsed or refractory diffuse large B-cell lymphoma

  This study is testing a new combination of two treatments for people with relapsed or hard-to-treat diffuse large B-cell lymphoma to see if it helps them respond better and live longer.

  Recruiting Phase 2 City of Hope Medical Center · Duarte, California · NCT05672251

• Testing new drug treatments after CAR T-cell therapy for relapsed or refractory lymphoma

  This study is testing if two new drugs can help people with lymphoma who haven't responded to previous CAR T-cell therapy feel better and live longer.

  Recruiting at 89 sites Phase 2 SWOG Cancer Research Network · Tucson, Arizona and 94 other locations · NCT05633615

• Using genetically modified T-cells and a vaccine to treat certain types of B-cell lymphoma after stem cell transplantation

  This study is testing a new treatment using specially modified immune cells and a vaccine to see if it can help people with certain types of B-cell lymphoma after they've had a stem cell transplant.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT05432635

• Combining Nivolumab and ASTX727 for B-Cell Lymphoma Treatment

  This study is testing a new combination of two treatments, nivolumab and ASTX727, to see if it can help people with relapsed or hard-to-treat B-cell lymphoma feel better and live longer.

  Recruiting at 8 sites Phase 1 National Cancer Institute (NCI) · Birmingham, Alabama and 8 other locations · NCT05272384

• CAR-T therapy for HIV-related aggressive B-cell lymphoma

  This study is testing a new CAR-T therapy to see if it can safely help people with HIV-related aggressive B-cell lymphoma that hasn't responded to other treatments.

  Recruiting at 7 sites Phase 1 AIDS Malignancy Consortium · Duarte, California and 6 other locations · NCT05077527

• Using ascorbic acid with chemotherapy to treat relapsed or refractory lymphoma and related conditions

  This study is testing if adding vitamin C to standard chemotherapy can help people with relapsed or hard-to-treat lymphomas and related blood conditions feel better.

  Recruiting Phase 2 Mayo Clinic · Mankato, Minnesota and 3 other locations · NCT03418038

Related topics

Quick answers

How many Recurrent Diffuse Large B-Cell Lymphoma clinical trials are recruiting right now?

20, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 2 countries. The most sites are in United States (19 trials), China (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 11, Phase 1: 7, Early Phase 1: 1, Phase 1/2: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →